Dry eye syndrome is incredibly common and prevalence is increasing globally. Studies show that prevalence rates vary from five to 50 per cent but can be as
high as 75 per cent in people over the age of 40, in people who wear contact lenses and those who work with computers. It is more common in women than in men,
particularly during and after the menopause.
According to a new real-world research commissioned by world experts in eye-care, Rohto, more than eight in ten women (83 per cent) indicate that they suffer from
the condition, but only once they have had the symptoms of dry eye syndrome described to them.
Without detailed explanation, 56 per cent of people say they have never even heard of dry eye syndrome, showing just how under diagnosed it may be.
Causes of dry eye
Dry eyes are a clinical cause of eye irritation, fatigue, and discomfort, often causing feelings of itchiness, grittiness, and excess watering. If left untreated,
dry eyes can even lead to long-term damage and sight problems.
Dry eyes may occur if enough tears aren't produced if poor-quality tears are generated or if the tears evaporate from the surface of the eye too quickly. This leads
to poor lubrication of the tear film. In a normal eye, the tear film4- the multilayer moist protective film - covers the cornea and lubricates the eye.
However, if the lubricative process is faulty dry spots appear on the surface of the eye and this causes irritation and discomfort. The tear film has several layers:
fatty oils, aqueous fluid, and mucus. This combination normally keeps the surface of your eyes lubricated, smooth and clear. But problems with any of these layers
can cause dry eyes.
PRES (Posterior Reversible Encephalopathy Syndrome) poses unique challenges during pregnancy, necessitating a deeper understanding of its implications.
About eighty-five percent of all women suffer from PMS or PMDD at some point in their lives. Premenstrual Syndrome is a dreadful condition that precedes your period and causes uncomfortable symptoms like backaches and cramps. Luckily, there are a number of tried remedies to live happier with PMS.
Depression, cramps, and headaches are some of the symptoms that mark the onset of the "Oh So Dreadful" days as most women associate with. These are the days when women suffer from Premenstrual Syndrome or PMS. It has become such a common term these days that it needs no introduction. Premenstrual Syndrome is a group of signs and symptoms that affect women during the week preceding the start of their period.
What are its main signs and symptoms of Urethral Syndrome?
Click link Continue to read this post of this disease Pain? what are the side effects? Treatment!
BioLight Life Sciences Investments announced that DiagnosTear has received all necessary approvals from Sheba Medical Center near Tel Aviv to begin a clinical study with its TeaRx, point-of-care Dry Eye Syndrome diagnostic assay.
US-based BioMarin Pharmaceutical has selected a new drug development candidate, BMN 250, for the treatment of Sanfilippo B syndrome or Mucopolysaccharidosis type IIIB (MPS IIIB).
n the modern world, everything is changing substantially. Significant changes are observed in all aspects of life style, eating habits, Medicine and Technology, Health and diseases.
n the modern world, everything is changing substantially. Significant changes are observed in all aspects of life style, eating habits, Medicine and Technology, Health and diseases.
Stroke is a cerebrovascular syndrome that involves the blockage and bursting of blood vessels in the brain. It shows a multifactorial pattern of inheritance. High cholesterol levels, high blood pressure, hypertension and obesity are the key causes of stroke besides inherited genes.
Ayurveda and Gynecology have a long-lasting connection since ages. In recent years, this connection has ignited the healthcare sector with the best of herbal and natural cure for gynaecological disorders. At Parijatak, we pamper you with the best of beneficial herbs, nutritional balance, panchakarma therapy, and Ayurvedic massages that are divine for polycystic ovary syndrome treatment, irregular menstruation treatment, and abnormal menstrual cycle treatment.
Oxford Cannabinoid Technologies Holdings plc, which specialises in developing cannabis-derived medicines with pain-relieving properties, has successfully
administered the first-in-human dose of its lead pharmaceutical drug compound, OCT461201, in its phase 1 clinical trial. The company holds a portfolio of four
drug candidates intended for use as licensed pain medications.
The drug is a selective cannabinoid receptor type 2 agonist with the potential to treat chemotherapy-induced peripheral neuropathy and irritable bowel syndrome.
The UK trial, conducted by Simbec Research Limited, part of Simbec-Orion Group Ltd., is progressing with healthy volunteers, OCTP said in a statement. Using a single
ascending dose protocol, the primary objective is to demonstrate OCT461201's safety and tolerability, while providing information on its pharmacokinetic profile, to
confirm its value as a potential drug.
Results from the trial, funded entirely by OCTP's existing resources, are expected in the third quarter of 2023, the statement added.
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a class 2 medicines recall for Sabril 500 mg film-coated tablets & Sabril 500 mg
granules for oral solution.
Sanofi UK has recalled the batches of Sabril tablets and Sabril granules as a precautionary measure due to the detection of traces of tiapride in the batches of the
source material of the manufacturer for vigabatrin.
Sabril (vigabatrin) is indicated for adjunctive treatment of focal seizures with or without secondary generalisation not satisfactorily controlled with other
antiepileptics (under expert supervision) and monotherapy in the treatment of infantile spasms (West's syndrome).
All patients are advised not to discontinue Sabril tablets or Sabril granules without consulting with their prescriber. The risks of suddenly stopping medication
for seizures/epilepsy is higher than the potential risk presented by the presence of tiapride.
Sanofi UK have confirmed to DHSC that no other batches are impacted, and other stock remains available.
Digestive issues such as constipation, dysphagia and irritable bowel syndrome (IBS) may be precursors of Parkinson's disease, according to research published
in the journal Gut.
Gastrointestinal symptoms are thought to precede the development of some cerebrovascular disease, including brain aneurysm or Alzheimer's disease, and it has been
suggested (Braak's hypothesis) that gut conditions may precede the development of Parkinson's disease too.
To test this hypothesis, researchers used data from a US nationwide medical record network (TriNetX) to compare 24,624 people who had been diagnosed with
Parkinson's disease of unknown cause with those who had been diagnosed with other neurological conditions - Alzheimer's disease (19,046) or cerebrovascular
disease (23,942) - or with none of these (24,624; comparison group).
Dr. Reddy's Teraleve® 4mg and 8mg Fesoterodine Fumarate Prolonged-Release tablets have been available in the UK since their launch on 1st June 2022.
Therapeutic indications:
Indicated in adults for treatment of the symptoms (increased urinary frequency and/or urgency and/or urgency incontinence) that may occur with overactive bladder
syndrome.
Presentation:
4mg tablets are light blue, oval, biconvex, film-coated, and engraved on one side with the number '4'.
8mg tablets are light blue, oval, biconvex, film-coated, and engraved on one side with the number '8'.
Tablets are packaged in aluminium-aluminium blisters in a carton with a PIL.
The National Institute for Health and Care Excellence (NICE) has recommended elosulfase alfa for routine use in the NHS for the treatment of mucopolysaccharidosis type 4A (also known as MPS 4A and Morquio A syndrome).
Elosulfase alfa, also called Vimizin and made by BioMarin, becomes the first disease modifying treatment recommended by NICE for routine NHS use for people with this rare, severely life-limiting condition.
NICE's final draft guidance follows the collection of 'real-world' data from 69 people who received NHS-funded treatment since 2015 as part of a managed access agreement. Clinical trial evidence and data collected as part of the managed access agreement, along with expert clinical opinion, shows some long-term benefits with elosulfase alfa treatment which suggest it slows progression of MPS 4A.